The most common injection site for simepaglutide is the abdomen, followed by the inner thighs, outer upper arms, and so on. Simeglutide is commonly used in the treatment of type 2 diabetes mellitus, and is usually administered by subcutaneous injection. The most common injection site is the abdomen, followed by the inner thighs, outer upper arms, etc. The site should be changed in the event of an adverse reaction such as infection of the injection site or fat atrophy. Care should be taken not to inject into skin areas with pits, thickenings, lumps, bruises, scars and other abnormalities. The most common adverse reactions to Simeglutide are gastrointestinal reactions such as nausea, vomiting, diarrhea and constipation to name a few. It is contraindicated in patients who are allergic to the components of the drug, have a history or family history of medullary thyroid cancer, and unexplained recurrent pancreatitis. Simeglutide should be used correctly under the guidance of a doctor to avoid the adverse consequences of blind use of the drug.